A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1657-1663

  Masi, Gianluca ^a,c   Falcone, Alfredo ^a   Di Paolo, Antonello ^b   Allegrini, Giacomo ^a   Danesi, Romano ^b   Barbara, Cecilia ^b   Cupini, Samanta ^a   Del Tacca, Mario ^b  

^a Civil Hospital   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Division of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTIEMETIC AGENT; CIPROFLOXACIN; DRUG METABOLITE; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; RALTITREXED; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; FEMALE; FLUOROURACIL; GLUCURONIDES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; PATIENT SELECTION; QUINAZOLINES; THIOPHENES; VOMITING;

EID: 1842481280     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1585-3     Document Type: Article

References (25)

1. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy (Ed. 2), pp. 463-484. Philadelphia: Lippincott-Raven, 1996.
2. O'Leary, J., and Muggia, F. M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer, 34: 1500-1508, 1998.
3. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., and Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
4. Rougier, P., Van Custem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P., and Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412, 1998.
5. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., and Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047, 2000.
6. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 343: 905-914, 2000.
7. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., and Ratain, M. J. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol., 15: 1502-1510, 1997.
8. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
9. Sparreboom, A., de Jonge, M. J. A., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H., Stoter, G., and Verweij, J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res., 4: 2747-2754, 1998.
10. Ryan, A. J., Squires, S., Strutt, H. L., and Johnson, R. T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res., 19: 3295-3300, 1991.
11. Gerrits, C. J., de Jonge, M. J., Schellens, J. H., Stoter, G., and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer, 76: 952-962, 1997.
12. Zhang, H., Wang, J. C., and Liu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA, 85: 1060-1064, 1988.
13. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
14. Furuta, T., and Yokokura, T. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Jpn. J. Cancer Chemother., 17: 121-130, 1990.
15. Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
16. Takimoto, C. H., Morrison, G., Harold, N., Quinn, M., Monahan, B. P., Band, R. A., Cottrell, J., Guemei, A., Llorens, V., Hehman, H., Ismail, A. S., Flemming, D., Gosky, D. M., Hirota, H., Berger, S. J., Berger, N. A., Chen, A. P., Shapiro, J. D., Arbuck, S. G., Wright, J., Hamilton, J. M., Allegra, C. J., and Grem, J. L. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J. Clin. Oncol., 18: 659-667, 2000.
17. Herben, V. M. M., Schellens, J. H. M., Swart, M., Gruia, G., Vernillet, L., Beijnen, J. H., and ten Bokkel Huinink, W. W. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J. Clin. Oncol., 17: 1897-1905, 1999.
18. Li, W. Y., and Koda, R. T. Stability of irinotecan hydrochloride in aqueous solutions. Am. J. Health Syst. Pharm., 59: 539-544, 2002.
19. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
20. Falcone, A., Di Paolo, A., Masi, G., Allegrini, G., Danesi, R., Lencioni, M., Pfanner, E., Comis, S., Del Tacca, M., and Conte, P. Sequence effect of irinotecan and 5-fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol., 19: 3456-3462, 2001.
21. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., and Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol., 19: 1501-1518, 2001.
22. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
23. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
24. Govindarajan, R. Irinotecan and thalidomide in metastatic colorectal cancer. Oncology (Basel), 14 (12 Suppl. 13): 29-32, 2000.
25. Govindarajan, R., Heaton, K. M., Broadwater, R., Zeitlin, A., Lang, N. P., and Hauer-Jensen, M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet, 356: 566-567, 2000.